Get started
Author

Delphine Mollon

Observed names: D. Mollon, D. Mollon Grange, Delphine MOLLON
Observed institutions: Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Centre Hospitalier de Cornouaille, Hôpital Laennec, Institut Curie
OpenAlex ID: A5016426762
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, François-Clément Bidard, et al. · The Lancet Oncology · 352
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
2021 · Joël Guigay, Anne Aupérin, et al. · The Lancet Oncology · 232
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma
2012 · Ronan Abgral, Pierre-Yves Le Roux, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 39
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025 · Hervé Bonnefoi, Florence Lerebours, et al. · The Lancet Oncology · 25
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients
2019 · Eric Voog, Boris Campillo‐Gimenez, et al. · International Journal of Cancer · 9
PDF
213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
2022 · M. Arnedos, A. Goncalves, et al. · Annals of Oncology · 8
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
2018 · Clémence Romeo, Florence Joly, et al. · Gynecologic Oncology · 5
Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3)
2021 · Hervé Bonnefoi, Florence Lerebours, et al. · Cancer Research · 4
Interest of high-resolution anoscopy in the assessment of tumoral inguinal adenopathy
2025 · Mathilde Osty, Christine Vaucher, et al. · Hépato-Gastro & Oncologie Digestive
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: the ENCOURAGE cohort of 1158 patients (pts) by GINECO
2016 · D. Berton-Rigaud, F. Selle, et al. · Annals of Oncology
Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): a phase 2 gineco study
2016 · B. You, F. Joly, et al. · Annals of Oncology
Works count: 11
Citation count: 674
H-index: 6
I10-index: 4
Year
Topic
Type